Mexiletine for myotonic dystrophy types 1 and 2
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a once-daily drug called mexiletine PR to see if it can help reduce muscle stiffness (myotonia) in people with myotonic dystrophy type 1 or 2. It may be a good option if you have a confirmed genetic diagnosis and are at least 16 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetic test showing myotonic dystrophy type 1 or 2.
- You need to be 16 years old or older and not pregnant or nursing.
- Your heart health must be normal, as checked by a doctor.
- You must have hand grip tightness that lasts 3 seconds or more.
- You should be able to walk 10 meters (with a cane or walker if needed).
- You cannot have had certain heart drugs or have a pacemaker.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a daily capsule of mexiletine is safe and helpful over 26 weeks for people with myotonic dystrophy type 1 or 2. It's for people who finished a previous related study and want to continue treatment.
This trial tests a one-time gene therapy (SAR446268) for people with non-congenital myotonic dystrophy type 1. It aims to see if the treatment is safe and can improve muscle symptoms like stiffness and weakness.
This study uses MRI scans to measure muscle changes in people with myotonic dystrophy (DM1 or DM2) and healthy volunteers. The goal is to find better ways to track the disease over time.
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
This trial compares a new extended-release (PR) form of mexiletine to the immediate-release (IR) form in people with non-dystrophic myotonias. The goal is to see if the longer-acting version works as well or better with fewer side effects.
This study follows children under 6 years old with genetic myotonic disorders who are taking or may take mexiletine. It helps doctors understand how well the medicine works and if it is safe over time.
Hear when a new Myotonic Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.